|
English
|
正體中文
|
简体中文
|
0
|
|
???header.visitor??? :
50694540
???header.onlineuser??? :
220
???header.sponsordeclaration???
|
|
|
|
???tair.name??? >
???browser.page.title.author???
|
"kwiatkowski"???jsp.browse.items-by-author.description???
Showing items 1-2 of 2 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 國立成功大學 |
2024-06 |
Vibostolimab coformulated with pembrolizumab (vibo/ pembro) plus chemotherapy (chemo) as first-line treatment for advanced esophageal cancer (ec): Results from cohort E of the phase II KEYVIBE-005 study
|
Hsu;C-H;Dziadziuszko;R;Abreo, Gomez;D, A.;Aksoy;S;Martin, Gil;M;Roderburg;C;Yen;C, J.;Arican;A;Cassier;P;Im;S-A;Kim;S-B;Kudo;T;Ochsenreither;S;Sendur;M, A. N.;Yonemori;K;Rojas;C, I.;Liu;Q;Keenan;T;Healy;J;Kwiatkowski;M |
| 國立成功大學 |
2024-01-20 |
Coformulated quavonlimab and pembrolizumab (pembro) in combination with lenvatinib (lenva) as first-line (1L) therapy for patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 2 KEYSTEP-004 study.
|
Rimassa;Lorenza;Li;Daneng;Ikeda;Masafumi;Yarchoan;Mark;Ryoo;Baek-Yeol;Kossler;Thibaud;Lim;Ho-Yeong;Kwiatkowski;Mariusz;Chang;Ting-Tsung;Kim;Hyun, Jee;Casadei-Gardini;Andrea;Kudo;Masatoshi;Ren;Zhenggang;Calvo;Varela, Maria;Llovet;Josep, M.;Zhang;Yayan;Hatogai;Ken;Siegel;Abby, B.;Cheng;Ann-Lii |
Showing items 1-2 of 2 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
